The biotech sector is in rude health despite concerns about raising funds. Its fortunes will improve further over the next five or six years as a number of big pharma players look to deal with feeble growth rates and less-than-compelling pipelines.
That is the view of Kasim Kutay, the CEO of Novo Holdings, who recently spoke to In Vivo during an...